Abstract Details

Title Two-Year Interim Analysis of Thyroid Abnormalities in a Trial of Alemtuzumab vs. High-Dose Interferon Beta-1a for Treatment of Relapsing-Remitting Multiple Sclerosis

Topic MS and Related Diseases

Presentation(s) (-)

Poster/Presentation
Number 087

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Alasdair Coles, MD, PhD (University of Cambridge)	Dr. Coles has nothing to disclose.
	No disclosure on file
Ricardo F. Allegri, MD, PhD, FAAN (Institute for Neurological Research (FLENI))	Dr. Allegri has nothing to disclose.
	No disclosure on file

��ɫ��

��ɫ��

Abstract Details

��ɫ����

��ɫ����

��ɫ��

��ɫ��